MYH16 Plays A Crucial Role in Tissue Development and Disease Progression

Target Name: MYH16

NCBI ID: G84176

MYH16

Other Name(s): MYH16P | MHC20 | myosin heavy chain 16 pseudogene | Myosin heavy chain 16 pseudogene | MYH5

MYH16 Plays A Crucial Role in Tissue Development and Disease Progression

Myeloid-derived suppressor protein (MYH16), also known as PDGF receptor alpha chain (PDGFRA), is a protein that is expressed in a variety of tissues, including blood, tissues, and organs. It plays a critical role in the development and maintenance of normal tissues, including blood cells, and has been implicated in the development and progression of many diseases, including cancer.

MYH16 is a transmembrane protein that is characterized by the presence of a extracellular domain, a transmembrane region, and an intracellular domain. The extracellular domain of MYH16 consists of a cytoplasmic region that is involved in the formation of a complex with other proteins, including colonies stimulating factor (CSF) and retinoic acid-regulated gene expression (RARA). The transmembrane region of MYH16 consists of a protein kinase catalytic domain and a pocket domain that is involved in protein-protein interactions. The intracellular domain of MYH16 Consists of a nuclear localization signal (NLS) and a tyrosine phosphorylation site that is involved in the regulation of cellular processes, including cell signaling and protein function.

MYH16 has been shown to play a critical role in the development and progression of many diseases, including cancer. For example, studies have shown that high levels of MYH16 are associated with poor prognosis in patients with various types of cancer, including breast, lung, and ovarian cancers. Additionally, MYH16 has been shown to be involved in the regulation of cellular processes, including cell signaling, cell adhesion, and angiogenesis.

MYH16 has also been shown to be a potential drug target in the treatment of various diseases. For example, inhibitors of MYH16 have been shown to have therapeutic potential in the treatment of breast, lung, and ovarian cancers. Additionally, MYH16 has been shown to be involved in the regulation of stem cell biology, and inhibitors of MYH16 have been shown to have therapeutic potential in the treatment of stem cell diseases, including beta-thalassemia and myelodysplastic syndromes.

In conclusion, MYH16 is a protein that plays a critical role in the development and maintenance of normal tissues, and has been implicated in the development and progression of many diseases. Additionally, MYH16 has been shown to be a potential drug target in the treatment of various diseases. Further research is needed to fully understand the role of MYH16 in disease progression and to develop effective therapies for the treatment of these diseases.

Protein Name: Myosin Heavy Chain 16 Pseudogene

Functions: Has most probably lost the function in masticatory muscles contraction suspected for its homologs in dog (AC F1PT61) and apes

The "MYH16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYH16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets